Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Backed by 40-plus years of experience, the new Grandview Max stakes it claim as this spring's open-toed outdoor overlord.

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Yes, we know, it's still February and yet we can't stop going on about hiking sandals, but what can we say? Our toes are ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital. In this article, we are going to take ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical ...